US Corporate Distress Financial Stress SEC Filings — March 02, 2026

02-03-2026

Allurion Technologies, Inc. received a NYSE notice of delisting due to failure to maintain at least $50M in stockholders’ equity or 30-trading day average market capitalization, triggering potential delisting proceedings. The company intends to appeal the decision, expects shares to continue trading on NYSE during the appeal, and is executing a plan to regain compliance, catalyzed by FDA approval on February 20, 2026, an agreement with its largest creditor to exchange debt for preferred stock, and a warrant inducement on February 24, 2026. While efforts are ongoing, there is no guarantee of regaining compliance or relisting on NYSE or another exchange like NYSE American.

• ·Discussions and negotiations ongoing with existing creditors and security holders, plus capital raising efforts.
• ·Previous announcements: agreement with largest creditor for debt-to-preferred stock exchange at a substantial premium to current trading price (subject to conditions).
• ·SEC filings referenced: 10-K filed March 27, 2025 (amended August 19, 2025); 10-Q filed November 17, 2025.

02-03-2026

Zymeworks Inc. announced a $250 million non-dilutive royalty-backed note financing from Royalty Pharma, secured by 30% of worldwide tiered royalties on Ziihera from Jazz Pharmaceuticals and BeOne Medicines, while retaining 70% of royalties during repayment and full rights thereafter. Proceeds will strengthen the balance sheet, fund stock repurchases at a perceived discount to intrinsic value, support potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks retains all milestone payments, including up to $1.5 billion in potential regulatory and commercial milestones.

• ·Repayment to Royalty Pharma from low to mid-single digit tiering royalties up to pre-specified limit, ceasing at 1.65x note by Dec 31, 2033 or 1.925x thereafter.
• ·Jazz royalties: tiered 10% to high teens on global sales (ex-Asia excl. Japan, Australia, NZ) up to $2.0B, 20% above.
• ·BeOne royalties: mid-single to mid-double digits up to $1.0B annual net sales, 19.5% above; holds marketing rights in Asia (ex-Japan), Australia, NZ.
• ·All regulatory and commercial milestones retained by Zymeworks.

02-03-2026

Kairos Pharma, Ltd. (NYSE American: KAPA) announced binding terms to acquire exclusive worldwide rights to CL-273, a next-generation AI-designed pan-EGFR inhibitor for EGFR-mutant NSCLC, from OrbiMed and Torrey Pines-backed Celyn Therapeutics, targeting a $16.2B market opportunity in 2026. CEO John Yu described the transaction as value-accretive and pivotal for expanding the oncology pipeline with a potentially best-in-class asset addressing resistance in lung cancer. No financial terms of the deal were disclosed, and completion remains subject to risks outlined in forward-looking statements.

• ·CL-273 is a reversible, wild-type-sparing small-molecule inhibitor targeting resistant EGFR mutations in NSCLC.
• ·EGFR mutations occur in 10-15% of Western NSCLC cases and up to 50% in Asian populations.
• ·Celyn Therapeutics focuses on small-molecule oncology drugs including EGFR- and c-MET-pathway inhibitors.
• ·ENV-105 is in Phase 2 for castrate-resistant prostate cancer and Phase 1 for NSCLC; not yet FDA-approved.
• ·D. Boral Capital, LLC acted as sole financial advisor.

02-03-2026

On March 1, 2026, Our Bond, Inc. (OBAI) amended warrants originally issued October 27, 2025, reducing the exercise price for 12,000,000 shares from $12.35 to discounted levels of $2.25 (4.5M shares), $2.75 (3.75M shares), and $3.25 (3.75M shares) for 90 days, after which it reverts to $12.35; 15,991,902 shares remain purchasable overall. Simultaneously, the company issued a $2.5M promissory note to Ascent Partners Fund, LLC at 10% interest, maturing September 1, 2026, requiring 25% of future securities offering proceeds toward repayment, with default penalties including 24% interest. This provides short-term financing but introduces dilution risk from lower warrant prices and debt obligations.

• ·Warrant original expiration: July 27, 2026
• ·Note events of default include failure to pay principal/interest within 5 business days, covenant breaches, defaults on indebtedness over $150,000, or change of control
• ·All other warrant terms unchanged post-amendment

02-03-2026

Rein Therapeutics, Inc. (RNTX) entered into a Securities Purchase Agreement dated February 2026 to sell an unsecured promissory note to a purchaser, as part of a series of notes with an aggregate principal amount of up to $5.5M, including a prior $2.5M note issued in January 2026. The notes include a 20% original issue discount on the purchase price. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Agreement closing to occur no earlier than first Business Day after February 2026 and no later than fifth Business Day after.
• ·SEC filing date: March 02, 2026.
• ·Exemption under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D.

02-03-2026

EACO Corp filed an 8-K on March 2, 2026, disclosing entry into a material definitive agreement under Item 1.01 and the creation of a direct financial obligation under Item 2.03, with related financial statements and exhibits under Item 9.01. No specific financial metrics, amounts, or performance comparisons were detailed in the filing notice. This represents a material event potentially impacting the company's capital structure.

• ·Filing CIK: 0000784539
• ·SIC: 5065 - WHOLESALE-ELECTRONIC PARTS & EQUIPMENT, NEC
• ·Fiscal Year End: August 31
• ·Business Address: 5065 E Hunter Ave, Anaheim, CA 92807

02-03-2026

Chaince Digital Holdings Inc. (CD) entered into a Securities Purchase Agreement on February 25, 2026, to sell 6,500,000 ordinary shares at $0.774 per share to non-U.S. investors for a total of $5.03M, under Regulation S exemption. The offering is expected to close on or before March 12, 2026. No financial performance metrics or period comparisons were reported.

• ·Securities registered: Common Shares, par value US$0.004 per share, trading symbol CD
• ·Exemption relied upon: Rule 903 of Regulation S under the Securities Act of 1933
• ·Principal executive offices: 1251 Avenue of the Americas, Fl 41, New York, NY 10019

02-03-2026

Paramount Skydance Corporation (PSKY) announced a definitive agreement to acquire Warner Bros. Discovery, Inc. (WBD) for $31.00 per share in cash, valuing WBD at $81B equity value and $110B enterprise value, funded by $47B in new Class B shares at $16.02 per share from the Ellison Family and RedBird Capital Partners, plus $54B in debt commitments. The deal, unanimously approved by both boards, is expected to close in Q3 2026 with over $6B in projected synergies and a net debt-to-EBITDA of 4.3x at close, unlocking expanded content libraries, streaming platforms, and sports rights. No historical declines or flat metrics are reported, positioning the combined entity for growth in DTC and theatrical releases with a minimum of 30 films annually.

• ·Expected net debt-to-EBITDA of 4.3x at closing, with path to investment grade within three years.
• ·Shareholder vote for WBD expected in early spring 2026.
• ·Conference call and webcast on March 2, 2026 at 8:30am ET.
• ·Transaction not subject to financing conditions; prior tender offer terminated.

02-03-2026

A consortium led by Global Infrastructure Partners (GIP) and EQT has agreed to acquire AES for $15.00 per share in cash, equating to a $10.7B equity value and $33.4B enterprise value, representing a 40.3% premium to the 30-day VWAP prior to July 8, 2025. The deal addresses AES's capital needs for growth beyond 2027, avoiding potential dividend reductions or significant equity issuances, while maintaining operations of AES Indiana and AES Ohio as regulated utilities. Transaction expected to close in late 2026 or early 2027, subject to approvals.

• ·Consortium to fund 100% of purchase price with equity; no expected impact on regulated utility customer rates.
• ·Fairness opinions provided by J.P. Morgan Securities LLC and Wells Fargo Securities LLC.
• ·AES cancelled Q4 and FY 2025 earnings call scheduled for March 3, 2026; expects to file 10-K on March 2, 2026.
• ·EQT total AUM EUR 270B (EUR 141B fee-generating) as of Dec 31, 2025.

02-03-2026

GeneDx Holdings Corp. entered into a $100M term loan agreement with Blackstone on February 27, 2026, to fully repay its existing credit agreement dated October 27, 2023, with Perceptive Credit Holdings IV, LP, and support balance sheet optimization and general corporate purposes. The new five-year loan bears interest at Term SOFR plus 4.50% (with a 1.50% floor), is secured by substantially all assets, and includes a $50M minimum liquidity covenant. No performance metrics or declines were reported in the filing.

• ·Term Loan prepayable at option but subject to yield protection premiums and mandatory prepayments on change of control, asset sales, or certain indebtedness.
• ·Obligations guaranteed by certain subsidiaries.
• ·Loan Agreement to be filed as exhibit to Q1 2026 10-Q.

02-03-2026

HCW Biologics Inc. (Nasdaq: HCWB) announced on March 2, 2026, that the Nasdaq Hearings Panel determined on February 26, 2026, the Company regained compliance with all continued listing rules for The Nasdaq Capital Market, avoiding delisting. This compliance enables continued access to public markets for capital to advance immunotherapies targeting autoimmune diseases, cancer, and senescence-associated diseases. CEO Dr. Hing C. Wong highlighted the Panel's discretion in providing time to meet the Equity Rule requirements.

• ·Phase 1 study for HCW9302 initiated in November 2025.
• ·Annual Report on Form 10-K filed with SEC on November 14, 2025.
• ·Two licensing agreements for exclusive worldwide rights to proprietary molecules.
• ·Pipeline details available at https://hcwbiologics.com/pipeline/

02-03-2026

Sabre Corporation adopted a limited-duration Shareholder Rights Plan effective March 1, 2026, expiring February 28, 2027, with a 15% ownership trigger (20% for passive investors) in response to Constellation Software Inc.'s accumulation of a 9.7% economic stake (4.7% beneficial ownership + 5% derivatives) between April and November 2025. Negotiations for a strategic governance agreement, including a board seat for Constellation's Vela Software CEO, neared completion but abruptly ended on February 26, 2026, without explanation, despite Sabre's reengagement attempts. The plan protects shareholders from creeping control without a premium but leaves room for fair offers or resumed talks.

• ·Rights issued one per share as of close of business March 11, 2026
• ·Constellation nomination notice delivered January 23, 2026; withdrew second candidate February 28, 2026
• ·Unusually high trading volume observed week of February 23-27, 2026
• ·Sabre remains open to resuming discussions with Constellation

02-03-2026

UroGen Pharma Ltd. and UroGen Pharma, Inc. entered into a $250M term loan agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and BioPharma Credit PLC, with $200M (Tranche A) funded on February 26, 2026, to refinance $125M existing debt and fund general corporate purposes, while $50M (Tranche B) is available by June 30, 2027. The loans carry 8.25% fixed interest, mature in approximately 5 years, with principal repayments in four quarterly installments starting Q1 2030, subject to fees including 1.5% funding fee and 1% exit fee, secured by substantially all assets, and include restrictive covenants but no financial covenants.

• ·Loan matures on 5th anniversary of Tranche A Closing Date (February 26, 2026).
• ·Prepayments before 1st anniversary subject to makewhole amount equal to interest through that date.
• ·No financial covenants; includes customary restrictive covenants on asset sales, indebtedness, dividends, and change of control.
• ·Obligations guaranteed by UroGen Pharma Ltd. (subject to Israeli law limitations) and secured by substantially all tangible and intangible assets.

02-03-2026

Pulmatrix, Inc. announced the termination of its Merger Agreement with Cullgen Inc. on February 28, 2026, following delays in approval from the China Securities Regulatory Commission, after stockholders approved the merger on June 16, 2025. Despite this termination, the company is advancing discussions on alternative merger opportunities and emphasized its iSPERSE™ technology, supported by 149 granted patents as of December 31, 2025, and pipeline assets like Phase 2-ready PUR3100, PUR1800, and partner-advanced PUR1900. No immediate financial impacts or monetization details from the termination were disclosed.

• ·Merger Agreement originally entered November 13, 2024, and amended April 7, 2025.
• ·Form S-4 registration statement filed February 14, 2025, effective May 9, 2025.
• ·Mutually agreed to waive 'No Solicitation' clause in December 2025 press release.
• ·PUR1900 approved for Phase 3 in India by Cipla; Pulmatrix and Cipla share U.S. rights 50/50.

02-03-2026

Signing Day Sports, Inc. terminated its At The Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC, which was entered into on December 2, 2024, for the offer and sale of common stock. The Company delivered a termination notice on February 27, 2026, effective March 10, 2026, with no sales occurring under the agreement since July 1, 2025. This ends the Company's ability to conduct further ATM offerings.

• ·Agreement originally filed as Exhibit 10.1 to Prior Form 8-K on December 2, 2024
• ·Trading symbol: SGN on NYSE American LLC
• ·No offers or sales of common stock under the ATM Agreement since July 1, 2025

02-03-2026

Intellia Therapeutics, Inc. amended its Open Market Sale Agreement with Jefferies LLC, increasing the total value of Common Shares issuable from $750M to $1,035,316,650, representing a 38% expansion of the ATM offering capacity. The amendment updates the issuance notice reference and changes the company contact from Glen Goddard to Edward Dulac. The company must file a Prospectus Supplement within two business days of March 2, 2026.

• ·Original Sales Agreement dated March 4, 2022, previously amended February 23, 2024
• ·Prospectus Supplement to be filed pursuant to Rule 424(b) within two Business Days
• ·Governed by New York law

02-03-2026

Classover Holdings Inc. (NASDAQ:KIDZ, KIDZW) terminated its $400M Equity Purchase Facility Agreement with Solana Strategic Holdings LLC, formally ending its Solana-focused digital asset treasury strategy, which the Board deemed no longer accretive under current market conditions. This move eliminates potential share dilution and redirects capital toward AI, AI agents, and robotics initiatives aligned with its educational technology mission. The company maintains a healthy balance sheet with no imminent liquidity needs and has not sold its existing Solana holdings, which will be evaluated for future divestment.

• ·Announcement date: March 2, 2026
• ·SEC filing date: March 02, 2026
• ·Items reported: 1.02, 9.01

02-03-2026

Gyre Therapeutics, Inc. (Nasdaq: GYRE) announced an all-stock agreement to acquire Cullgen Inc. for approximately $300 million, creating a U.S.- and China-based fully integrated biopharmaceutical company with commercial assets like ETUARY® ($105.8M net sales in 2024) and Cullgen's TPD/DAC pipeline targeting inflammatory diseases, cancers, and pain. Leadership will transition with Dr. Ying Luo becoming President and CEO while Ping Zhang remains Executive Chairman; the deal is expected to close early Q2 2026 subject to approvals. Cullgen's prior proposed merger with Pulmatrix was terminated, introducing some prior uncertainty.

• ·Gyre Pharmaceuticals plans NDA submission for Hydronidone in China H1 2026 with conditional approval and priority review eligibility, followed by Phase 3c confirmatory trial.
• ·Cullgen's CG001419 completed Phase 1 for acute pain (positive top-line late 2025), IND submitted for Phase 2 in bunionectomy patients, and in Phase 1 for solid tumors.
• ·Cullgen's CG009301 in Phase 1 for blood cancers including relapsed/refractory AML, higher-risk MDS, and ALL.
• ·Hydronidone received Breakthrough Therapy designation by CDE/NMPA in March 2021.
• ·Updated corporate presentation posted on gyretx.com and cullgen.com.

02-03-2026

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a private placement priced at-the-market under Nasdaq rules, issuing 6,372,550 shares (or pre-funded warrants) and two series of warrants to purchase up to 6,372,550 shares each at $0.51 per share, expecting $3.25M upfront gross proceeds and up to $6.5M additional if warrants are fully exercised. H.C. Wainwright & Co. acts as exclusive placement agent, with closing expected on or about February 27, 2026, subject to customary conditions; proceeds for debt repayment and working capital. No assurance is given that warrants will be exercised.

• ·Purchase price and warrant exercise price: $0.51 per share
• ·Series A-1 warrants expire five years from stockholder approval; Series A-2 expire eighteen months from approval
• ·Warrants exercisable beginning on effective date of stockholder approval
• ·Securities offered under Section 4(a)(2) and Regulation D to accredited investors; registration rights for resale
• ·Press release dated February 26, 2026; 8-K filing March 02, 2026

02-03-2026

Rallybio Corporation (RLYB) and Candid Therapeutics announced a definitive merger agreement, with Rallybio acquiring Candid; the combined entity will operate as Candid Therapeutics (CDRX) with pro-forma cash of approximately $700M from over $505M concurrent financing, funding operations through 2030 and advancing TCE pipeline including Phase 2 for cizutamig in 2026. However, pre-merger Rallybio equityholders will own only 3.65% of the combined company (Candid 96.35%), representing significant dilution, while Rallybio shareholders receive CVRs linked to legacy asset sales like REV102.

• ·Merger expected to close mid-2026, subject to stockholder approval, HSR waiting period, and other conditions.
• ·CND319 first-in-human studies planned for mid-2026.
• ·Joint conference call held March 2, 2026 at 8:30 AM ET.

02-03-2026

On February 27, 2026, The Cannabist Company Holdings Inc. entered into a further extension of a forbearance agreement with an ad hoc group of noteholders holding the Company's 9.25% Senior Secured Notes due December 31, 2028, and 9.00% Senior Secured Convertible Notes due December 31, 2028, extending the forbearance period until March 6, 2026. This prevents noteholders from exercising rights and remedies under the indenture amid presumed covenant or payment issues. The agreement signals ongoing financial pressures with no disclosed resolution or positive developments.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 321 Billerica Road, Chelmsford, Massachusetts 01824.

02-03-2026

On March 1, 2026, Antares Strategic Credit Fund II LLC (the Fund) and Antares Capital Credit Advisers LLC (the Adviser) entered into a waiver letter agreement extending the prior waiver of base management fees and incentive fees payable to the Adviser through August 31, 2026. This waiver applies to fees under the Investment Advisory Agreement dated June 26, 2025. No financial amounts or performance metrics were disclosed in the filing.

• ·Agreement filed as Exhibit 10.1
• ·Investment Advisory Agreement originally dated June 26, 2025

02-03-2026

Purebase Corporation (PUBC) entered into an unsecured $1M line of credit agreement with affiliate CORETER LLC on February 27, 2026, at 8% annual interest, maturing one year later on February 27, 2027. Lender may convert outstanding principal and interest into common stock at maturity based on the weighted average closing price of the prior 20 trading days. Proceeds are designated for payroll, unpaid invoices, and operating expenses; the agreement is unsecured with no immediate advances specified.

• ·Loan advances require 3 business days written notice and are at Lender's sole discretion.
• ·Unsecured obligations; no registration rights for the Note or potential Conversion Shares under Securities Act.
• ·Related-party transaction as CORETER LLC is an affiliate of Borrower.

02-03-2026

LSI Industries Inc. (Nasdaq: LYTS) announced a proposed $90 million public offering of common stock, with a 30-day underwriter option for up to an additional 15% of shares, to fund its growth strategy including the Royston Group acquisition (merger agreement dated February 20, 2026, expected to close in Q3 FY2026) and repayment of borrowings under a January 21, 2026 credit facility. Proceeds may also support general working capital. The announcement highlights forward-looking risks such as market conditions, integration challenges, and economic factors, with no current performance metrics provided.

• ·Agreement and Plan of Merger dated February 20, 2026
• ·Senior Secured Credit Facility Commitment Letter dated January 21, 2026
• ·Expected Royston Group acquisition close in third quarter of LSI’s 2026 fiscal year
• ·Oppenheimer & Co. and Craig-Hallum acting as joint lead book-running managers
• ·LSI headquartered in Cincinnati with 18 manufacturing plants in US and Canada

02-03-2026

Booz Allen Hamilton Inc. entered into the Eleventh Amendment to its Credit Agreement on February 27, 2026, establishing $1B in new Refinancing Revolving Commitments (replacing existing ones), $750M in new Refinancing Tranche A-2 Term Loans to partially repay existing Tranche A Term Loans, and $500M in Supplemental Revolving Commitments, resulting in total Revolving Commitments of $1.5B. Existing Revolving Loans and part of Existing Tranche A Term Loans will be repaid in full or in part on the Effective Date, with waivers of certain prepayment penalties. No material negative impacts or declines in financial metrics are disclosed.

• ·Existing Revolving Commitments and Revolving Loans to be terminated/repaid on Eleventh Amendment Effective Date.
• ·Proceeds of $750M New Refinancing Tranche A-2 Term Loans used solely to repay part of Existing Tranche A Term Loans.
• ·Waivers of prepayment losses/expenses for Term SOFR Loans prepaid before end of Interest Period.
• ·Letters of Credit outstanding to remain in place post-termination of Existing Revolving Commitments.
• ·Effectiveness subject to no Default/Event of Default, true representations/warranties, and payment of fees.

02-03-2026

MariMed Inc. entered into a Restructuring and Exchange Agreement dated February 24, 2026, with Navy Capital Green entities, cancelling existing promissory notes totaling $4.4175M and surrendering 4,908,333 Series B shares valued at $14.725M to avoid mandatory conversion or redemption provisions due February 28, 2026. In exchange, the Company issued new promissory notes for an $8M loan ($2M Note 1 and $6M Note 2, guaranteed by subsidiaries) and 26,900,000 new Series B Convertible Preferred shares. While this provides restructuring flexibility and new liquidity, it introduces additional debt and significant potential equity dilution.

• ·Existing Shares issued originally at $3.00 per share and convertible 1:1 into common stock.
• ·New Series B Preferred Stock issuance upon filing amended Series B Certificate of Designation with Delaware Secretary of State.
• ·Company to pay Navy's costs, expenses, and fees within 3 business days of Effective Date.
• ·Transactions exempt from registration under Regulation D and state securities laws.

02-03-2026

Fidus Investment Corporation entered into Amendment No. 3 to its Equity Distribution Agreement, increasing the maximum aggregate offering amount under its at-the-market (ATM) program from $300.0M to $400.0M. As of March 2, 2026, approximately $134.8M remains available for sale through sales agents Fidus Investment Advisors, LLC, Raymond James & Associates, Inc., and B. Riley Securities, Inc. No shares were sold in connection with this amendment.

• ·Original Equity Distribution Agreement dated November 10, 2022
• ·Prospectus supplement filed March 2, 2026 (accompanying prospectus dated February 27, 2026)
• ·Shelf registration on Form N-2 (File No. 333-293856)

02-03-2026

DHI Group, Inc. (NYSE: DHX) announced the acquisition of Point Solutions Group, an engineering and technology professional services firm in defense contracting, for $5.5 million, including $5.0 million upfront cash and $0.5 million potential earn-out based on 2026 revenue thresholds. The deal enables ClearanceJobs to bid on federal contracts, provide staffing solutions for cleared roles, and expand its market beyond job postings. No financial impacts or declines were disclosed in the announcement.

• ·Acquisition announced on March 2, 2026
• ·Point Solutions Group holds Top Secret facility clearance and past performance on U.S. Department of Defense and intelligence community contracts
• ·Earn-out achievable within one year of purchase date

02-03-2026

Bakkt Holdings, Inc. announced the pricing of a $48.125M registered direct offering of 3,024,799 shares of Class A common stock and pre-funded warrants to purchase 2,475,201 shares at approximately $8.75 per share/warrant to a single institutional investor, expected to close on or around March 2, 2026. Gross proceeds will fund working capital, general corporate purposes, and strategic initiatives, with Cohen & Company Capital Markets as sole placement agent. No comparative financial metrics were provided, and the announcement includes extensive forward-looking risk disclosures but no quantitative declines.

• ·Offering pursuant to shelf registration statement on Form S-3 (File No. 333-288361) effective July 3, 2025.
• ·Pricing announced February 27, 2026; expected closing on or around March 2, 2026, subject to customary conditions.
• ·Pre-funded warrants have $0.0001 per share exercise price.

02-03-2026

On March 2, 2026, My Size, Inc. received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), as the closing bid price fell below $1.00 for 30 consecutive business days. The company has 180 calendar days until August 31, 2026, to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days, with potential for an additional 180 days if other listing standards are met. The Notification Letter has no immediate effect on trading, but failure to comply could lead to delisting proceedings, and the company may consider a reverse stock split.

• ·Trading symbol: MYSZ
• ·State of incorporation: Delaware
• ·Commission File Number: 001-37370
• ·IRS Employer Identification No.: 51-0394637
• ·Principal executive offices: HaNegev 4, POB 1026, Airport City, Israel 7010000
• ·Telephone: +972-3-600-9030

02-03-2026

Pitney Bowes Inc. completed a $150M offering of additional 7.250% Senior Notes due 2029 on March 2, 2026, which form a single series with $326M of original notes issued in 2021, increasing total outstanding Notes to $476M. The company received net proceeds of approximately $146.9M, to be used for general corporate purposes including repayment, repurchase, or refinancing of other indebtedness. The notes are senior unsecured obligations guaranteed by certain U.S. subsidiaries.

• ·Interest payable semi-annually in arrears on March 15 and September 15; first payment for Additional Notes on March 15, 2026, including accrued interest from September 15, 2025.
• ·Notes mature on March 15, 2029, unless earlier repurchased or redeemed.
• ·Issued pursuant to Original Indenture dated March 19, 2021, supplemented by First Supplemental Indenture dated March 2, 2026.

02-03-2026

Lifeward Ltd. (LFWD) completed a 1-for-12 reverse share split effective February 24, 2026, reducing outstanding Ordinary Shares from 18,339,098 to approximately 1,528,098 to comply with Nasdaq Capital Market's $1.00 minimum bid price listing requirement. The company simultaneously adopted its Eighth Amended and Restated Articles of Association, increasing authorized Ordinary Shares from 75,000,000 to 100,000,000. Outstanding warrants and stock options were proportionately adjusted.

• ·Shareholder approval at Extraordinary General Meeting on January 6, 2026.
• ·Finance Committee approved 1-for-12 ratio on January 30, 2026, and amendments on February 16, 2026.
• ·Trading on split-adjusted basis began February 24, 2026, under symbol LFWD with new CUSIP M8216Q309.
• ·No fractional shares issued; fractions rounded down.

02-03-2026

Voya Financial, Inc. completed a $400M registered public offering of 5.050% Senior Notes due 2036 on March 2, 2026, fully guaranteed by its wholly-owned subsidiary Voya Holdings Inc., yielding net proceeds of approximately $395.2M after commissions and expenses. Proceeds are intended for general corporate purposes, potentially including repayment of the $447M outstanding 3.65% Senior Notes due June 15, 2026. No declines or flat metrics reported in this debt issuance event.

• ·Notes issued under Base Indenture dated July 13, 2012, supplemented by Tenth Supplemental Indenture dated March 2, 2026.
• ·Interest payable semi-annually on March 2 and September 2, beginning September 2, 2026.
• ·Voya may redeem Notes in whole or in part at any time at prices specified in Supplemental Indenture.
• ·Underwriting Agreement dated February 23, 2026, with Citigroup Global Markets Inc., BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives.

02-03-2026

HA Sustainable Infrastructure Capital, Inc. issued $400M aggregate principal amount of 6.000% Green Senior Unsecured Notes due 2036 on March 2, 2026, under an amended indenture dated June 24, 2025. Net proceeds will temporarily repay borrowings under the revolving credit facility, commercial paper programs, or redeem outstanding 8.00% Senior Notes due 2027, with ultimate allocation to eligible green projects within two years. The Notes are senior unsecured obligations guaranteed by key subsidiaries, with semi-annual interest payments starting September 15, 2026, and maturity on March 15, 2036.

• ·Base Indenture dated June 24, 2025; Officer’s Certificate dated March 2, 2026.
• ·Optional redemption: prior to Dec 15, 2035 at 100% principal plus make-whole premium; on/after Dec 15, 2035 at 100% principal.
• ·Interest payable semi-annually on March 15 and September 15, commencing September 15, 2026.

02-03-2026

Northann Corp. received NYSE American acceptance on February 24, 2026, of its compliance plan submitted by January 7, 2026, granting until June 8, 2027, to regain compliance with continued listing standards under Section 1003(a)(i) of the Company Guide. While the company's common stock (NCL, $0.001 par value) remains listed and traded with no immediate impact on operations or SEC reporting, failure to meet progress goals or full compliance by the deadline could trigger delisting proceedings. The company affirmed its intent to pursue all reasonable measures during this Plan Period, following an initial non-compliance notice on December 11, 2025.

• ·Initial non-compliance notice filed December 11, 2025
• ·Company is an emerging growth company
• ·Principal executive office: 2251 Catawba River Rd., Fort Lawn, SC 29714
• ·Trading symbol: NCL on NYSE American LLC

02-03-2026

Acrivon Therapeutics, Inc. mutually terminated its OncoSignature Companion Diagnostic Agreement with Akoya Biosciences (a Quanterix subsidiary), dated June 17, 2022, effective February 25, 2026, with no financial payments exchanged. The termination enables transition of ACR-368 OncoSignature testing to Acrivon's newly certified in-house CLIA laboratory, completed February 18, 2026, providing full control over development, biomarkers, and commercialization rights. Quanterix will support ongoing clinical testing needs during the transition for Acrivon's registrational-intent Phase 2b study.

• ·Termination involves transfer of all procedures, materials, and know-how from Akoya to Acrivon
• ·Supports streamlining of co-regulatory approvals and co-commercialization of therapeutics and diagnostics

02-03-2026

Targa Resources Corp. completed a public offering of $750M aggregate principal amount of 4.350% Senior Notes due 2031 and $750M aggregate principal amount of 6.050% Senior Notes due 2056, totaling $1.5B in senior unsecured notes guaranteed by certain subsidiaries. The notes were issued under an indenture dated April 6, 2022, as supplemented on March 2, 2026, with U.S. Bank Trust Company, National Association as trustee. Net proceeds will be used for general corporate purposes, including repaying commercial paper borrowings, other indebtedness, repurchasing securities, capital expenditures, working capital, or subsidiary investments.

• ·Prospectus Supplement dated February 25, 2026, filed February 26, 2026
• ·Base Indenture dated April 6, 2022

02-03-2026

On February 24, 2026, the Nasdaq Listing and Hearing Review Council affirmed the Nasdaq Hearings Panel's decision to delist Graphjet Technology's Class A ordinary shares due to failures under Listing Rules 5450(b)(2) (market value of listed securities) and 5450(b)(3)(C) (market value of publicly held shares), with delisting effective November 13, 2025. Despite the company's appeal on November 25, 2025, proposing compliance under Rule 5450(b)(1) with at least $10M stockholders' equity and $5M market value of publicly held shares, the decision was upheld with no path to reinstatement noted. This represents a significant negative development with no offsetting positive metrics.

• ·Trading suspended on Nasdaq on November 13, 2025.
• ·Panel delisting determination dated November 11, 2025.
• ·Appeal filed November 25, 2025 (Docket No. NQ 7187N-25), acknowledged November 26, 2025.
• ·Company incorporated in Cayman Islands; principal offices in Shah Alam, Selangor, Malaysia.
• ·Emerging growth company status confirmed.

02-03-2026

Neuronetics, Inc. entered into a Second Amendment to the Registration Rights Agreement with Madryn Asset Management LP and its affiliates (the 'Madryn Parties') on March 2, 2026, stemming from the prior Arrangement Agreement with Greenbrook TMS Inc. The amendment obligates Neuronetics to file a Registration Statement for resale of all Registrable Securities owned by the Madryn Parties within five business days after filing its Annual Report on Form 10-K for the year ended December 31, 2025, upon receipt of a Shelf Notice. In exchange, the Madryn Parties commit to voting their Neuronetics shares at the 2026 annual meeting in accordance with the Board of Directors' recommendations on specified proposals.

• ·First Amendment to Registration Rights Agreement executed on November 1, 2024
• ·Original Registration Rights Agreement executed August 13, 2024
• ·Second Amendment attached as Exhibit 10.1

02-03-2026

Vista Gold Corp. announced a proposed underwritten public offering of US$30.0 million in common shares, with a 30-day underwriter option for up to an additional US$4.5 million to cover over-allotments, led by CIBC Capital Markets. Net proceeds are intended for exploration and development at the Mt. Todd gold project in Australia and general corporate purposes. The offering is subject to market conditions, TSX approval, and other factors, with no assurance of completion or final terms.

• ·Shelf registration on Form S-3 (No. 333-282706) filed October 17, 2024, effective November 8, 2024.
• ·Offering also in Canadian provinces except Quebec under listed issuer financing exemption.
• ·Closing subject to TSX approval under Section 602.1 exemption.

02-03-2026

Fortitude Gold Corp. (OTCQB: FTCO) entered a Joint Venture Agreement with Hawthorne Land & Minerals, LLC to form East Camp Douglas, LLC, funded by Hawthorne's $40M investment for 40% ownership while Fortitude retains 60% majority interest and operational control. The investment supports an aggressive exploration program aiming for a major gold discovery within 1-2 years, parallel permitting for up to 125 acres disturbance, and fast-tracked mine development. No declines or flat performance metrics reported in current operations.

• ·Property located in Silver Star mining district, Mineral County, Nevada, ~6 miles southwest of Mina.
• ·Consists of 293 unpatented lode claims, 24 unpatented placer claims, 12 patented mining claims, and 3 fee land parcels.
• ·Ongoing exploration under two active Notices of Intent (NOIs) for limited 5-acre disturbance while permitting progresses.
• ·Year-end conference call to discuss JV to be announced separately.

02-03-2026

Kratos Defense & Security Solutions, Inc. (KTOS) announced a proposed underwritten public offering of $1B in common stock pursuant to an effective shelf registration, with underwriters holding a 30-day option for up to an additional $150M in shares. Net proceeds are expected to fund customer-targeted acquisitions, investments and capital expenditures for national security programs and pipeline opportunities, and general corporate purposes. The offering is subject to market and other conditions, with no assurance of completion.

• ·Shelf registration on Form S-3ASR (File No. 333-293786) automatically effective February 26, 2026.
• ·Joint book-running managers: Baird, Raymond James, RBC Capital Markets, Truist Securities.
• ·Announcement date: February 26, 2026; 8-K filing date: March 02, 2026.

02-03-2026

Resolute Holdings Management, Inc. converted from a Delaware corporation to a Nevada corporation and adopted new Articles of Incorporation effective upon filing. The new articles authorize 1,100,000,000 total shares (1,000,000,000 Common Stock and 100,000,000 Preferred Stock, both with $0.0001 par value), establish a classified board of up to 12 directors divided into three classes, and include provisions limiting stockholder actions by written consent and special protections tied to 'Investor' ownership exceeding 40% of voting power. No financial performance metrics or period-over-period changes are reported.

• ·Filing Date: March 02, 2026
• ·No cumulative voting for Common Stock
• ·Directors may only be removed for cause by 2/3 vote of voting power
• ·Board authorized to fill vacancies without stockholder vote
• ·No preemptive or subscription rights for Common Stock holders
• ·Trigger Date occurs when Investors cease to beneficially own 40% of voting power

02-03-2026

Omnicom Group Inc. closed public offerings of $1.7B in U.S. Dollar-denominated senior notes ($400M 4.200% due 2029, $700M 5.000% due 2033, $600M 5.300% due 2036) and €600M 3.850% senior notes due 2034 issued by subsidiary Omnicom Finance Holdings plc, generating net proceeds of ~$1.68B and ~€594.5M. Proceeds will primarily repay $1.4B of 3.600% senior notes due April 15, 2026 (outstanding as of Dec 31, 2025), with remainder for general corporate purposes including acquisitions, debt repayment, and stock repurchases. The notes are unsecured senior obligations with standard covenants, redemption options, and change of control repurchase rights at 101%.

• ·U.S. Notes interest payable semi-annually: Mar 2/Sep 2 for 2029 Notes (commencing Sep 2, 2026); Jun 2/Dec 2 for 2033/2036 Notes (commencing Jun 2, 2026).
• ·Euro Notes interest payable annually on May 2 (commencing May 2, 2026).
• ·Redemption: U.S. Notes make-whole prior to Feb 2, 2029 (2029 Notes)/Apr 2, 2033 (2033)/Mar 2, 2036 (2036) at gov't bond rate +15-20 bps; par thereafter. Euro Notes make-whole prior to Feb 2, 2034 at +20 bps; par thereafter.
• ·Underwriting agreements dated Feb 25, 2026; U.S. Notes Indenture dated Mar 2, 2026; Euro Notes Second Supplemental Indenture dated Mar 2, 2026.
• ·Euro Notes listing application approved by NYSE.

02-03-2026

Duos Technologies Group, Inc. (Nasdaq: DUOT) announced the commencement of an underwritten public offering of common stock (or equivalents) to expand and commercialize its Edge Data Center business, with proceeds also for working capital and general corporate purposes. Titan Partners, a division of American Capital Partners, is the sole bookrunner, and the offering includes a potential 30-day underwriter option for additional shares. However, the offering is subject to market conditions with no assurance of completion, timing, size, or terms.

• ·Shelf registration statement on Form S-3 (File No. 333-293372) filed February 11, 2026, declared effective February 12, 2026.
• ·Preliminary prospectus supplement to be filed with SEC and available at www.sec.gov.
• ·Contact for prospectus: Titan Partners Group LLC, 4 World Trade Center, 49th Floor, New York, NY 10007, (929) 833-1246, prospectus@titanpartnersgrp.com.
• ·Websites: www.duostech.com, www.duosedge.ai, www.duosenergycorp.com.

02-03-2026

Iterum Therapeutics plc received a Nasdaq delisting determination on February 24, 2026, for noncompliance with the $1.00 minimum bid price rule and other standards including the $35M minimum market value of listed securities, shareholders' equity, and net income requirements. Ordinary shares face suspension from Nasdaq trading effective March 5, 2026, unless the company appeals to a hearings panel. The company is evaluating strategic alternatives, including potential wind-down, bankruptcy, or liquidation, where shareholders are unlikely to receive meaningful returns.

• ·Compliance period for Minimum MVLS Requirement extends until June 9, 2026.
• ·Nasdaq intends to file Form 25-NSE with SEC after appeal periods lapse.
• ·Company may file Form 15 to suspend reporting obligations post-delisting.

02-03-2026

TriplePoint Venture Growth BDC Corp. entered into a Master Note Purchase Agreement dated February 27, 2026, authorizing the issuance and sale of $75M aggregate principal amount of 7.50% Series 2026 Senior Notes due February 27, 2028. The notes include provisions for interest rate adjustments upward by 1.00% upon a Below Investment Grade Event or Secured Debt Ratio Event, providing flexibility but potential cost increases for the company.

• ·Agreement filed as Exhibit 10.1 in 8-K on March 02, 2026.
• ·SEC filing items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).
• ·Below Investment Grade Event defined based on ratings from NRSROs; company required to maintain at least one Investment Grade rating per Section 9.8.
• ·Secured Debt Ratio calculated excluding SBIC Subsidiaries, with pro forma adjustments for projected cash from asset sales, equity, or unsecured debt within 60 days.